Wave Life Sciences

Yahoo Finance • 27 days ago

Top movers analysis one hour before the close of the markets on 2025-09-03: top gainers and losers in today's session.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT STI [https://www.chartmill.com/stock/quote/STI/profile] 86.59% SOLIDION TECHN... Full story

Yahoo Finance • 27 days ago

Wednesday's session: gap up and gap down stocks

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT STI [https://www.chartmill.com/sto... Full story

Yahoo Finance • 27 days ago

Wave Life Sciences reports durable AAT protein production with repeat doses of WVE-006; stock down 21%

[Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.] Wave Life Sciences (NASDAQ:WVE [https://see... Full story

Yahoo Finance • 27 days ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically... Full story

Yahoo Finance • last month

WAVE Life Sciences stock maintains Buy rating at Canaccord ahead of data

Investing.com - WAVE Life Sciences (NASDAQ:WVE), currently trading at $9.51 with analyst targets ranging from $9 to $36, maintained its Buy rating from Canaccord Genuity, which reiterated its $19.00 price target as the company prepares to... Full story

Yahoo Finance • last month

Tan Aik Na sells Wave Life Sciences (WVE) shares for $194k

Director Tan Aik Na of Wave Life Sciences LTD (NASDAQ:WVE) sold 21,000 shares of the company’s stock on August 15, 2025, at a price of $9.25, for a total value of $194,250. The transaction comes as Wave Life Sciences, currently valued at $... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences gains as JPMorgan suspends rating

[Duchenne muscular dystrophy genetic test] Hailshadow/iStock via Getty Images * Wave Life Sciences (NASDAQ:WVE [https://seekingalpha.com/symbol/WVE]) quickly hit highs of the day, rising 5%, after JPMorgan suspended its rating, price ta... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences director Henry sells $85k in shares

Christian O. Henry, a director at Wave Life Sciences LTD (NASDAQ:WVE), sold 9,670 ordinary shares of the company on August 13, 2025, for approximately $85,192. The stock, currently trading at $8.76, has shown remarkable strength with a 57%... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts

[FDA headquarters in Washington DC.] JHVEPhoto Canaccord Genuity initiated RNA-based drug developer Wave Life Sciences (NASDAQ:WVE [https://seekingalpha.com/symbol/WVE]) with a Buy recommendation and a $19 per share target on Monday, citi... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advance

Earnings Call Insights: Wave Life Sciences Ltd. (WVE) Q2 2025 MANAGEMENT VIEW * Paul B. Bolno, President and CEO, highlighted entering the second half of 2025 with strong momentum, noting "we continue to extend our leadership in RNA ed... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares

Wave Life Sciences Ltd (NASDAQ:WVE [https://www.chartmill.com/stock/quote/WVE]) reported its second-quarter 2025 financial results, missing analyst revenue estimates but showing a narrower-than-expected loss per share. The company posted r... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences GAAP EPS of -$0.31 misses by $0.02, revenue of $8.7M misses by $0.94M

* Wave Life Sciences press release [https://seekingalpha.com/pr/20182472-wave-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:WVE [https://seekingalpha.com/symbol/WVE]): Q2 GAAP EPS of -$... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first c... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webca... Full story

Yahoo Finance • 2 months ago

Wave Life Sciences' SWOT analysis: RNA editing stock poised for breakthrough

Wave Life Sciences Ltd . (NASDAQ:WVE), with a market capitalization of $1.23 billion, is at the forefront of developing RNA editing oligonucleotides for genetic diseases, with a diverse pipeline targeting multiple indications. According to... Full story

Yahoo Finance • 2 months ago

Citi initiates coverage on WAVE Life Sciences stock with Buy rating

Investing.com - Citi has initiated coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating and a price target of $16.00, citing multiple near-term catalysts that could drive upside potential. According to InvestingPro data, analyst c... Full story

Yahoo Finance • 3 months ago

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 4, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE), retaining the price targ... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best CRISPR stocks to buy. On June 23, H.C. Wainwright maintained its $22 price target and Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE). The rating, in line with the strong analyst... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences' SWOT analysis: RNA editing stock faces fierce competition

Wave Life Sciences Ltd . (NASDAQ:WVE) is at the forefront of developing innovative RNA-based therapeutics, with a particular focus on its proprietary RNA editing platform. The company’s pipeline spans multiple indications, including alpha-... Full story

Yahoo Finance • 3 months ago

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Prof... Full story